leisure time -WSS

leisure time

author：comprehensive 2025-10-02 23:48:27 - browse：2313

Have you ever seen a mouse with a set of muscles more appropriate for a bodybuilder or comic book superhero?

Well, 25 years ago, researchers at Johns Hopkins University made it happen. By silencing a gene responsible for producing a protein called myostatin, they directed tiny mouse bodies to grow double the amount of lean muscle they would normally, leading to mice with bulky arms, defined pectorals, and an overall more substantial body mass. They were dubbed “mighty mice.”

Now, biotech startups are hoping to use those findings to create what they believe will be better weight loss medications. In the last several months, multiple companies have disclosed they are testing drugs that preserve or grow muscle while reducing fat, as shown in the updated STAT Obesity Drug Tracker. They hope that their drugs, possibly when used in conjunction with existing obesity treatments, will result in healthier weight loss.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： ChatGPT in medicine: STAT answers readers' burning questions
Next article： In boost for rare disease push, AstraZeneca to buy Amolyt Pharma

Wikipedia

WSS

RaDonda Vaught links Vanderbilt hospital issues to patient death

UCLA team creates talking throat patch for voice disorders

As AI in medicine takes off, can 'human in the loop' prevent harm?

RaDonda Vaught links Vanderbilt hospital issues to patient death

Hospitals are dialing back on venture capital investing

Be careful with at

focus

leisure time

hotspot

Indiana Supreme Court upholds abortion ban, says state constitution gives only limited protections

Acadia's Nuplazid fails as schizophrenia medicine in Phase 3 study

DIEP, the 'gold standard' of breast reconstruction, is under threat

First U.S. drug developed to treat liver disease MASH is approved

Wildfire smoke exposes gaps in outdoor worker protections

Schizophrenia gene found to be linked to cells' energy dysfunction

Alkermes shareholders re

Readout Newsletter: Bristol, Sangamo, Gilead, and more

Medical records are filled with copy

John Green on his newest strategy for fighting tuberculosis

entertainment

Acadia's Nuplazid fails as schizophrenia medicine in Phase 3 study

Biden administration begins canceling student loan debt for 804,000 borrowers

YouTube cracks down on misinformation on cancer treatment

R.J. Reynolds sues to protect 'crisp' cigs from California flavor ban

EPA limits use of carcinogenic gas for sterilizing medical devices

In boost for rare disease push, AstraZeneca to buy Amolyt Pharma

Wikipedia

focus

entertainment

entertainment